05.17.23
SeraNovo, based in Leiden, The Netherlands, closed a multi-compound deal with AstraZeneca.
Niall Hodgins, Chief Executive Officer of SeraNovo said, “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with AstraZeneca.”
SeraNovo is a formulation technology provider that provides services to enhance the bioavailability of poorly soluble Active Pharmaceutical Ingredients (APIs). The company specializes in addressing two core issues with its technology: enhancing bioavailability and reducing development time to the clinic.
Niall Hodgins, Chief Executive Officer of SeraNovo said, “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with AstraZeneca.”
SeraNovo is a formulation technology provider that provides services to enhance the bioavailability of poorly soluble Active Pharmaceutical Ingredients (APIs). The company specializes in addressing two core issues with its technology: enhancing bioavailability and reducing development time to the clinic.